Supernus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	718.95	661.82	607.52	667.24	579.78
Revenue Growth (YoY)	8.63%	8.94%	-8.95%	15.09%	11.41%
Cost of Revenue	180.8	77.91	83.78	87.22	75.06
Gross Profit	538.16	583.91	523.74	580.02	504.71
Selling, General & Admin	412.66	335.78	336.36	377.22	304.76
Research & Development	-	108.8	91.59	74.55	90.47
Amortization of Goodwill & Intangibles	89.46	77.98	82.39	82.63	29.99
Operating Expenses	502.12	522.56	510.34	534.4	425.22
Operating Income	36.04	61.36	13.4	45.61	79.5
Interest Expense	-	-	-2.42	-7.07	-23.42
Interest & Investment Income	13.25	-	-	-	10.22
Other Non Operating Income (Expenses)	-	16.2	10.45	21.68	-
EBT Excluding Unusual Items	49.29	77.55	21.44	60.22	66.3
Merger & Restructuring Charges	-72.9	-	-	-	-
Gain (Loss) on Sale of Investments	-	0.01	-	0.01	0.35
Asset Writedown	-	-	-20.19	-	-
Other Unusual Items	-25.42	6.11	1.52	0.51	6.53
Pretax Income	-49.03	97.87	2.77	60.74	73.18
Income Tax Expense	-10.48	24.01	1.45	0.03	19.75
Net Income	-38.55	73.87	1.32	60.71	53.42
Net Income to Common	-38.55	73.87	1.32	60.71	53.42
Net Income Growth	-	5512.84%	-97.83%	13.64%	-57.92%
Shares Outstanding (Basic)	56	55	55	54	53
Shares Outstanding (Diluted)	56	56	56	62	54
Shares Change (YoY)	0.88%	0.81%	-10.01%	13.47%	1.24%
EPS (Basic)	-0.68	1.34	0.02	1.13	1.01
EPS (Diluted)	-0.68	1.32	0.02	1.04	0.98
EPS Growth	-	6500.00%	-98.08%	6.32%	-58.48%
Free Cash Flow	-	171.23	110.53	116.41	125.08
Free Cash Flow Per Share	-	3.06	1.99	1.89	2.30
Gross Margin	74.85%	88.23%	86.21%	86.93%	87.05%
Operating Margin	5.01%	9.27%	2.21%	6.84%	13.71%
Profit Margin	-5.36%	11.16%	0.22%	9.10%	9.21%
Free Cash Flow Margin	-	25.87%	18.19%	17.45%	21.57%
EBITDA	124.77	141.77	98.26	131.16	112.09
EBITDA Margin	17.35%	21.42%	16.17%	19.66%	19.33%
D&A For EBITDA	88.73	80.41	84.86	85.54	32.6
EBIT	36.04	61.36	13.4	45.61	79.5
EBIT Margin	5.01%	9.27%	2.21%	6.84%	13.71%
Effective Tax Rate	-	24.53%	52.47%	0.05%	26.99%
Revenue as Reported	718.95	661.82	607.52	667.24	579.78

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q